20.90
1.46%
0.40
Pharvaris Nv (PHVS) 最新ニュース
(PHVS) Long Term Investment Analysis - Stock Traders Daily
Pharvaris Reports 93% HAE Attack Reduction in Trial Data, Plans Phase 3 Study | PHVS Stock News - StockTitan
Pharvaris to Present HAE Treatment Progress at Guggenheim Healthcare Conference | PHVS Stock News - StockTitan
Trend Tracker for (PHVS) - Stock Traders Daily
Axonis Therapeutics Announces $115 Million Series A Financing - Financial Times
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting - StockTitan
(PHVS) Proactive Strategies - Stock Traders Daily
Pharvaris (PHVS) Shares Cross Above 200 DMA - Nasdaq
PHVSPharvaris N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at ... - The Hastings Tribune
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings - StockTitan
Pharvaris to Host Virtual Investor Event on October 23, 2024 - StockTitan
(PHVS) Investment Report - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Gap DownShould You Sell? - MarketBeat
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at - The Bakersfield Californian
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop - StockTitan
Novo Holdings A S Buys 556,970 Shares of Pharvaris (NASDAQ:PHVS) - MarketBeat
Pharvaris N.V.'s SWOT analysis: promising HAE drug boosts stock outlook - Investing.com India
Pharvaris CBO Resigns, Team Absorbs Duties - TipRanks
(PHVS) Technical Data - Stock Traders Daily
Hereditary Angioedema Therapeutics Global Market Report Explores 2024: Size Forecast and Growth Prospects 2033 - WhaTech
Pharvaris (NASDAQ:PHVS) Shares Gap Down to $21.09 - MarketBeat
EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma - sharewise
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Paradise, NV – Injuries Reported in Vehicle Accident on I-215 W near Las Vegas Blvd Onramp - Local Accident Reports
Las Vegas, NV – Accident on I-215 E near Windmill Ln Results in Injuries - Local Accident Reports
North Las Vegas Man Charged in Fatal Hit-and-Run After Allegedly Fleeing Accident Scene - Hoodline
Paradise, NV – Vehicle Accident at I-215 E and Las Vegas Blvd - Local Accident Reports
Las Vegas, NV – Vehicle Accident at CC215 S and W Sunset Rd Causes Injuries - Local Accident Reports
Highway reopens outside Las Vegas after crash, fire in semi hauling lithium batteries - KRNV
Road closures persist after trucks carrying wood and batteries collide - News3LV
Appeal over identifying invasive hornets in Jersey - BBC.com
Hwy 95 closes in Nye County after crash involving truck carrying lithium batteries - Audacy
1 person transported to hospital after Henderson crash involving bicyclist - Fox 5 Las Vegas
1 hospitalized in Henderson crash involving bicyclistKLAS - KLAS - 8 News Now
Oregon man dies northwest of Las Vegas Valley, state police say - Fox 5 Las Vegas
1 person taken to hospital after crash involving car, bicyclist in Henderson - News3LV
Rep. Steven Horsford releases updated campaign ad after LVPPA concerns - KTNV 13 Action News Las Vegas
Silver Springs man killed in crash on U.S. 50A & 6th Street in Fernley - KTVN
Las Vegas, NV – Collision at CC215 S & W Flamingo Rd Results in Injuries - Local Accident Reports
Pharvaris (NASDAQ:PHVS) Shares Gap Up After Analyst Upgrade - MarketBeat
Pharvaris stock outlook strengthened with price target increase, Outperform rating reiterated by Oppenheimer - Investing.com UK
(PHVS) Technical Pivots with Risk Controls - Stock Traders Daily
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and ... - The Bakersfield Californian
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant - StockTitan
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024 - StockTitan
Pharvaris Presents Data at the Bradykinin Symposium 2024 - StockTitan
Pharvaris to Present at SVB Securities Global Biopharma Conference - Yahoo Finance UK
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium - Yahoo Finance UK
Pharvaris (NASDAQ:PHVS) Shares Gap Down to $19.08 - MarketBeat
Pharvaris (NASDAQ:PHVS) Stock Price Up 5.2% - MarketBeat
Pharvaris (NASDAQ:PHVS) Trading Down 2.4% - MarketBeat
(PHVS) Trading Advice - Stock Traders Daily
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
Pharvaris (NASDAQ:PHVS) Shares Up 5.1% - MarketBeat
Price T Rowe Associates Inc. MD Sells 84,783 Shares of Pharvaris (NASDAQ:PHVS) - Defense World
(PHVS) Investment Analysis and Advice - Stock Traders Daily
Viridian, Pharvaris said to be among prime M&A targets for Biogen - Seeking Alpha
Contrasting Avidity Biosciences (NASDAQ:RNA) and Pharvaris (NASDAQ:PHVS) - American Banking and Market News
Pharvaris (NASDAQ:PHVS) Price Target Raised to $38.00 at Oppenheimer - Defense World
大文字化:
|
ボリューム (24 時間):